{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:46:51Z","timestamp":1790804811634,"version":"4.1.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Fatigue and fatigability are commonly reported in spinal muscular atrophy (SMA). Physical fatigability, proposed to be the most relevant to SMA pathophysiology, encompasses performance-based and perceived physical fatigability (PPF) assessments. While performance-based measures have highlighted physical fatigability as an SMA hallmark, PPF is not well characterized due to the lack of disease- and construct-specific scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Our aim was to create a patient-reported outcome measure tailored for SMA, named the SMA EFFORT, to improve PPF assessment. Here, we describe the scale development process, assess scale properties, and discuss future research and application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>SMA and scale development experts organized a comprehensive physical activity item bank, relevant across the SMA phenotypic spectrum. Activities were systematically categorized by varying intensities and durations. The SMA EFFORT was completed by an international cohort of individuals with all types of SMA. To compare PPF across demographic and clinical variables, SMA EFFORT PPF percent (PPF%) composite scoring was established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      One hundred eighteen participants completed the SMA EFFORT. Total PPF% scores were broadly distributed within functional groups, with differences between non-sitters (35.1\u2009\u00b1\u200921.0) and sitters (24.9\u2009\u00b1\u200915.1) (\n                      <jats:italic toggle=\"yes\">p\u2009<\/jats:italic>\n                      =\u20090.006), and those with (34.4\u2009\u00b1\u200918.1) and without respiratory support (26.4\u2009\u00b1\u200917.8) (\n                      <jats:italic toggle=\"yes\">p\u2009<\/jats:italic>\n                      =\u20090.02). Participants treated with disease modifying therapy (DMT) showed similar scores to those without treatment (\n                      <jats:italic toggle=\"yes\">p\u2009<\/jats:italic>\n                      =\u20090.70). Further, no differences in scores were observed in participants with scoliosis surgery and those without (\n                      <jats:italic toggle=\"yes\">p\u2009<\/jats:italic>\n                      =\u20090.71). Subscale analyses revealed differences in mean PPF% subscale scores by functional group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The novel SMA EFFORT standardizes PPF ratings by anchoring activity to intensity and duration. Item and scale data insights will inform the next iteration, which will undergo additional investigation. The SMA EFFORT aims to improve upon current measures to better assess treatment impact on physical well-being across the SMA spectrum.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/22143602241313326","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T05:46:47Z","timestamp":1738302407000},"page":"45-56","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Development of the SMA EFFORT: A new approach to characterize perceived physical fatigability in spinal muscular atrophy"],"prefix":"10.1177","volume":"12","author":[{"given":"Rafael","family":"Rodriguez-Torres","sequence":"first","affiliation":[{"name":"Departments of Rehabilitation and Regenerative Medicine, Columbia University Irving Medical Center, New York, NY, USA"},{"name":"Neurology, Columbia University Irving Medical Center, New York, NY, USA"},{"name":"Department of Biobehavioral Sciences, Teacher's College, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara H","family":"Kanner","sequence":"additional","affiliation":[{"name":"Departments of Rehabilitation and Regenerative Medicine, Columbia University Irving Medical Center, New York, NY, USA"},{"name":"Department of Biobehavioral Sciences, Teacher's College, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L","family":"Gay","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Uher","sequence":"additional","affiliation":[{"name":"Departments of Rehabilitation and Regenerative Medicine, Columbia University Irving Medical Center, New York, NY, USA"},{"name":"Department of Biobehavioral Sciences, Teacher's College, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Corbeil","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Area Mental Health Data Science, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Coratti","sequence":"additional","affiliation":[{"name":"Centro Clinico Nemo, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"},{"name":"Pediatric Neurology, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Dunaway Young","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurosciences, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Rohwer","sequence":"additional","affiliation":[{"name":"Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Muni Lofra","sequence":"additional","affiliation":[{"name":"The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"McDermott","sequence":"additional","affiliation":[{"name":"Departments of Biostatistics and Computational Biology, and Neurology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl C","family":"De Vivo","sequence":"additional","affiliation":[{"name":"Neurology, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M","family":"Wall","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Area Mental Health Data Science, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy W","family":"Glynn","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Montes","sequence":"additional","affiliation":[{"name":"Departments of Rehabilitation and Regenerative Medicine, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2670"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01356-1"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90460-3"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2020.11.009"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2012.12.053"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/338627"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.12.1831"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180342"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00552-y"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011230"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.07.007"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51353"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2021-000164"},{"key":"e_1_3_4_16_2","article-title":"Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2\u20134","volume":"5","author":"Stam M","year":"2023","unstructured":"Stam M, et al. Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2\u20134. Brain Commun 2023; 5: fcac324.","journal-title":"Brain Commun"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1244-3"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00001-6"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00367-7"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26633"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221600"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68051-w"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01498-2"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/PHM.0000000000001869"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103458"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13191"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827f07be"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/15459683211046257"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-1016-5_39"},{"key":"e_1_3_4_32_2","article-title":"Patient reported outcome measures in adult spinal muscular atrophy: a scoping review and graphical visualization of the evidence","author":"Slayter J","year":"2022","unstructured":"Slayter J, Casey L, O\u2019Connell C. Patient reported outcome measures in adult spinal muscular atrophy: a scoping review and graphical visualization of the evidence. J Neuromuscul Dis 2022; 10: 239\u2013250","journal-title":"J Neuromuscul Dis"},{"key":"e_1_3_4_33_2","article-title":"Fatigue and fatigability in spinal muscular atrophy; a proposed taxonomy to enhance assessment and treatment","author":"Rodriguez-Torres R","year":"2024","unstructured":"Rodriguez-Torres R, Montes J. Fatigue and fatigability in spinal muscular atrophy; a proposed taxonomy to enhance assessment and treatment. Muscle Nerve. Epub ahead of print 2024.","journal-title":"Muscle Nerve"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/1609406919887274"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.08.014"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2015.1134306"},{"key":"e_1_3_4_37_2","unstructured":"Team R.C. R: A language and environment for statistical computing. 2024. Available from: https:\/\/www.R-project.org\/."},{"key":"e_1_3_4_38_2","volume-title":"Mplus user\u2019s guide","author":"Muth\u00e9n LK","year":"1998","unstructured":"Muth\u00e9n LK, Muth\u00e9n BO. Mplus user\u2019s guide. 8th ed. Los Angeles, CA: Muth\u00e9n & Muth\u00e9n, 1998\u20132017.","edition":"8"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-021-10351-y"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1348-2"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d3e308"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurop.2022.06.008"},{"key":"e_1_3_4_43_2","article-title":"Validation of a set of instruments to assess patient- and caregiver-oriented measurements in spinal muscular atrophy: results of the SMA-TOOL study","author":"V\u00e1zquez-Costa JF","year":"2022","unstructured":"V\u00e1zquez-Costa JF, et al. Validation of a set of instruments to assess patient- and caregiver-oriented measurements in spinal muscular atrophy: results of the SMA-TOOL study. Neurol Ther 2022; 12: 89\u2013105.","journal-title":"Neurol Ther"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/16501970510030156"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10227-5"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11030367"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2021.100266"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2022.07.012"},{"key":"e_1_3_4_49_2","unstructured":"FDA U.S. Focus area: patient-reported outcomes and other clinical outcome assessments. 09\/06\/2022]. Available from: https:\/\/www.fda.gov\/science-research\/focus-areas-regulatory-science-report\/focus-area-patient-reported-outcomes-and-other-clinical-outcome-assessments (accessed 12 May 2024)."}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602241313326","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/22143602241313326","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602241313326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:52:52Z","timestamp":1777506772000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/22143602241313326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/22143602241313326"],"URL":"https:\/\/doi.org\/10.1177\/22143602241313326","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}